CardioVax is a Los Angeles based biotechnology company developing novel immunotherapies for the treatment of cardiovascular disease, the number one cause of death globally.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

PDS BIOTECH ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH THE FDA AND PREPARATION FOR THE REGISTRATIONAL TRIAL

PDS Biotechnology | October 04, 2022

news image

PDS Biotechnology Corporation a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® for the treatment of unresectable, recurrent/metastatic human papilloma virus 16-positive head and neck squamous cell carcinoma. Read More

ARBOR VITA LAUNCHES OPEN PLATFORM COVID-19 ANTIBODY TEST EXPANDING ACCESS TO HIGHER QUALITY DIAGNOSTICS

Arbor Vita | June 08, 2020

news image

Arbor Vita announced today the availability of its CoVisa™ IgG ELISA-based test for antibodies associated with the novel coronavirus (COVID-19). The test has been found to have a 100 percent sensitivity (positive percentage agreement), and 99.24 percent specificity (negative percentage). Additional validation testing is ongoing in independent laboratories. The company has notified the U.S. Food and Drug Administration under the Emergency Use Authorization (EUA) process.Arbor Vita'...

Read More

KANE BIOTECH WELCOMES RENOWNED CANADIAN VETERINARIAN, DR. JEAN GAUVIN, AS CHIEF VETERINARY OFFICER

BioSpace | February 20, 2020

news image

Kane Biotech Inc. (TSX-V:KNE) (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced that it has appointed Jean Gauvin, DVM, as its Chief Veterinary Officer (“CVO”), effective immediately. In the newly-created position of CVO, Dr. Gauvin will serve as a liaison between Kane Biotech and industry, guide the K...

Read More

Cell and Gene Therapy

VIZGEN RELEASES COMMERCIAL MERSCOPE PLATFORM

Vizgen | August 31, 2021

news image

Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced shipment of the first commercial MERSCOPETM Platforms, marking the successful start of their limited summer release program. These first platforms are being purchased by leading research institutes including the Salk Institute, the University of California, Irvine, and the Beth Israel Deaconess Medical Center. Vizgen will continue shipping a limited number...

Read More
news image

Industrial Impact

PDS BIOTECH ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH THE FDA AND PREPARATION FOR THE REGISTRATIONAL TRIAL

PDS Biotechnology | October 04, 2022

PDS Biotechnology Corporation a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® for the treatment of unresectable, recurrent/metastatic human papilloma virus 16-positive head and neck squamous cell carcinoma. Read More

news image

ARBOR VITA LAUNCHES OPEN PLATFORM COVID-19 ANTIBODY TEST EXPANDING ACCESS TO HIGHER QUALITY DIAGNOSTICS

Arbor Vita | June 08, 2020

Arbor Vita announced today the availability of its CoVisa™ IgG ELISA-based test for antibodies associated with the novel coronavirus (COVID-19). The test has been found to have a 100 percent sensitivity (positive percentage agreement), and 99.24 percent specificity (negative percentage). Additional validation testing is ongoing in independent laboratories. The company has notified the U.S. Food and Drug Administration under the Emergency Use Authorization (EUA) process.Arbor Vita'...

Read More
news image

KANE BIOTECH WELCOMES RENOWNED CANADIAN VETERINARIAN, DR. JEAN GAUVIN, AS CHIEF VETERINARY OFFICER

BioSpace | February 20, 2020

Kane Biotech Inc. (TSX-V:KNE) (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced that it has appointed Jean Gauvin, DVM, as its Chief Veterinary Officer (“CVO”), effective immediately. In the newly-created position of CVO, Dr. Gauvin will serve as a liaison between Kane Biotech and industry, guide the K...

Read More
news image

Cell and Gene Therapy

VIZGEN RELEASES COMMERCIAL MERSCOPE PLATFORM

Vizgen | August 31, 2021

Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced shipment of the first commercial MERSCOPETM Platforms, marking the successful start of their limited summer release program. These first platforms are being purchased by leading research institutes including the Salk Institute, the University of California, Irvine, and the Beth Israel Deaconess Medical Center. Vizgen will continue shipping a limited number...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us